Acer Therapeutics to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on therapies for rare and life-threatening diseases, will present at the H.C. Wainwright Global Investment Conference from September 13-15, 2021. The presentation will be available on demand starting September 13 at 7 AM ET, along with one-on-one investor meetings. Acer’s pipeline includes ACER-001 for inborn errors of metabolism, ACER-801 for vasomotor symptoms, EDSIVO™ for vascular Ehlers-Danlos syndrome, and ACER-2820 for infectious diseases. More details can be found on their website.

NEWTON, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021.

Conference:		H.C. Wainwright 23rd Annual Global Investment Conference
Format:		Virtual on demand presentation and one-on-one meetings
Presentation:		Available on demand beginning September 13, 2021 at 7 AM ET
Webcast:		https://www.acertx.com/investor-relations/events-presentations/

About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced vasomotor symptoms (iVMS); EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. In March 2021, Acer entered into a Collaboration and License Agreement with Relief Therapeutics for development and commercialization of ACER-001. For more information, visit www.acertx.com.

Investor Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 617-430-7578
hans@lifesciadvisors.com

Jim DeNike
Acer Therapeutics Inc.
Ph: 844-902-6100
jdenike@acertx.com

FAQ

When is Acer Therapeutics presenting at the H.C. Wainwright Global Investment Conference?

Acer Therapeutics will present at the H.C. Wainwright Global Investment Conference from September 13-15, 2021.

How can I access Acer Therapeutics' presentation from the investment conference?

Acer’s presentation will be available on demand starting September 13, 2021, at 7 AM ET.

What therapies are in Acer Therapeutics' pipeline?

Acer's pipeline includes ACER-001, ACER-801, EDSIVO™, and ACER-2820.

What is ACER-001 developed by Acer Therapeutics?

ACER-001 is sodium phenylbutyrate, aimed at treating inborn errors of metabolism, including urea cycle disorders.

What is the purpose of the H.C. Wainwright Global Investment Conference?

The conference allows companies like Acer Therapeutics to present their strategies and meet with investors.